Discovery Labs jumps on positive clinical trial data

NancyCesarano

NEW YORK (CBS.MW) -- Shares of Discovery Laboratories Inc.
dsco
jumped more than 15 percent to $7.85 after the Warrington, Pa.-based biopharmacuetical company reported positive results from a phase II trial of Surfaxin, its proposed treatment for acute respiratory distress syndrome in adults. The company said the patient groups received Surfaxin showed a 31 percent relative improvement in overall mortality versus the current standard of care after 28 days.

Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.